Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

Ítems similars

• Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population
  per: Kozlowski, Steven, et al.
  Publicat: (2020)
• Influenza vaccination coverage estimates in the fee-for service Medicare beneficiary population 2006 – 2016: Using population-based administrative data to support a geographic based near real-time tool
  per: Shen, Angela K., et al.
  Publicat: (2018)
• Uptake of Infliximab Biosimilars Among the Medicare Population
  per: Chen, Alice J., et al.
  Publicat: (2020)
• Precision and Robustness of 2D-NMR for structure assessment of filgrastim biosimilars
  per: Ghasriani, Houman, et al.
  Publicat: (2016)
• Association between filgrastim biosimilar availability and changes in claim payments and Patient out-of-pocket costs for biologic Filgrastim Products
  per: Mouslim, Morgane C., et al.
  Publicat: (2020)